Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans

Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers

NCT03443830•Tychan Pte Ltd.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Treatment of Acute Zika Virus Infection

Interventions

Tyzivumab

Locations

Singapore

Locations (1)

SingHealth Investigational Medicine Unit

Singapore, Singapore

Key Dates

Start Date

February 8, 2018

Primary Completion Date

September 12, 2018

Completion Date

December 4, 2018

Last Updated

April 10, 2019

Sponsors

Lead Sponsor

Tychan Pte Ltd.

Collaborators

Duke-NUS Graduate Medical School
Singapore Clinical Research Institute
National University of Singapore
National University Hospital, Singapore

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 10, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions